CTI BioPharma Corp.
Hedge Funds Holdings
Last updated:
CTI BioPharma Corp.‘s stocks are currently a part of 142 hedge funds’ portfolios, which represents 86.37% of the total amount of its stocks outstanding. This makes up a total of 105.01M shares of CTI BioPharma Corp.. Compared to the previous quarter, the number grew by 7.53% or 7.35M shares more. As for the holding position changes, 32.39% (46) of current hedge fund investors increased the number of shares held, 26.06% (37) of current holders sold a part of the shares held, and 19.01% (27) closed the holdings completely. 42 hedge funds are new holders of CTI BioPharma Corp. stock in Q4 2022, it is 29.58% of total holders.
Hedge funds holding CTI BioPharma Corp. (Q1 2018 – Q4 2022)
| Q1 2018 | 58 |
|---|---|
| Q2 2018 | 73 |
| Q3 2018 | 70 |
| Q4 2018 | 61 |
| Q1 2019 | 57 |
| Q2 2019 | 45 |
| Q3 2019 | 33 |
| Q4 2019 | 30 |
| Q1 2020 | 29 |
| Q2 2020 | 32 |
| Q3 2020 | 29 |
| Q4 2020 | 55 |
| Q1 2021 | 49 |
| Q2 2021 | 41 |
| Q3 2021 | 51 |
| Q4 2021 | 53 |
| Q1 2022 | 80 |
| Q2 2022 | 109 |
| Q3 2022 | 126 |
| Q4 2022 | 142 |
Hedge funds changes in CTI BioPharma Corp. positions (Q1 2018 – Q4 2022)
| Q1 2018 | 26 | 19 | 3 | 7 | 3 |
|---|---|---|---|---|---|
| Q2 2018 | 31 | 21 | 9 | 16 | -4 |
| Q3 2018 | 11 | 21 | 20 | 14 | 4 |
| Q4 2018 | 7 | 21 | 14 | 16 | 3 |
| Q1 2019 | 7 | 11 | 20 | 11 | 8 |
| Q2 2019 | 8 | 8 | 16 | 18 | -5 |
| Q3 2019 | 1 | 9 | 13 | 13 | -3 |
| Q4 2019 | 6 | 7 | 7 | 9 | 1 |
| Q1 2020 | 6 | 12 | 4 | 6 | 1 |
| Q2 2020 | 6 | 7 | 8 | 3 | 8 |
| Q3 2020 | 5 | 8 | 8 | 9 | -1 |
| Q4 2020 | 30 | 8 | 9 | 4 | 4 |
| Q1 2021 | 8 | 21 | 10 | 13 | -3 |
| Q2 2021 | 4 | 17 | 10 | 12 | -2 |
| Q3 2021 | 14 | 12 | 14 | 4 | 7 |
| Q4 2021 | 13 | 17 | 15 | 10 | -2 |
| Q1 2022 | 30 | 23 | 16 | 3 | 8 |
| Q2 2022 | 47 | 34 | 19 | 17 | -8 |
| Q3 2022 | 28 | 45 | 43 | 10 | 0 |
| Q4 2022 | 42 | 46 | 37 | 27 | -10 |
Hedge funds changes in CTI BioPharma Corp. stock options (Q1 2018 – Q4 2022)
| Q1 2018 | 451,000 | 60,000 |
|---|---|---|
| Q2 2018 | 512,000 | 217,000 |
| Q3 2018 | 119,000 | 21,000 |
| Q4 2018 | 34,000 | 0 |
| Q1 2019 | 88,000 | 101,000 |
| Q2 2019 | 169,000 | 61,000 |
| Q3 2019 | 34,000 | 0 |
| Q4 2019 | 189,000 | 0 |
| Q1 2020 | 32,000 | 0 |
| Q2 2020 | 34,000 | 0 |
| Q3 2020 | 541,000 | 122,000 |
| Q4 2020 | 748,000 | 195,000 |
| Q1 2021 | 443,000 | 580,000 |
| Q2 2021 | 1,103,000 | 600,000 |
| Q3 2021 | 287,000 | 431,000 |
| Q4 2021 | 1,072,000 | 570,000 |
| Q1 2022 | 3,145,000 | 2,571,000 |
| Q2 2022 | 6,569,000 | 3,152,000 |
| Q3 2022 | 5,826,000 | 7,214,000 |
| Q4 2022 | 14,510,190 | 470,887 |